Get the Stockscreener App
0.167
3.15%
0.0051
Pre-market:
.17
0.003
+1.80%
Gossamer Bio Inc stock is traded at $0.167, with a volume of 16.12M.
It is up +3.15% in the last 24 hours and down -50.88% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
See More
Previous Close:
$0.1619
Open:
$0.17
24h Volume:
16.12M
Relative Volume:
1.43
Market Cap:
$81.64M
Revenue:
$55.54M
Net Income/Loss:
$-180.40M
P/E Ratio:
-0.212
EPS:
-0.7877
Net Cash Flow:
$-170.32M
1W Performance:
+0.85%
1M Performance:
-50.88%
6M Performance:
-95.59%
1Y Performance:
-86.53%
1-Day Range:
$0.1658
$0.18
1-Week Range:
$0.14
$0.1835
52-Week Range:
$0.14
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.167 | 81.64M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Context Capital Management, LLC Acquires Significant Stake in Go - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
D. E. Shaw (GOSS) discloses 9.5% stake after major exchange offer - Stock Titan
David E. Shaw Discloses Investment at Gossamer Bio with 9.5% Stake - TradingView
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
683 Capital reports 49.87M-share position in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Investors to Reach Out - ACCESS Newswire
2026-06-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Investors to Reach Out | NDAQ:GOSS | Press Release - Stockhouse
Massive recapitalization at Gossamer Bio (NASDAQ: GOSS) could give noteholders majority control - Stock Titan
Context Capital (GOSS) discloses 48.8M-share, 9.9% stake in Gossamer Bio - Stock Titan
Gossamer Bio (NASDAQ: GOSS) awards 115K stock options to director - Stock Titan
Gossamer Bio (GOSS) director Skye Drynan awarded 115,000 stock options at $0.178 - Stock Titan
Gossamer Bio (GOSS) director receives 115,000 stock options as board compensation grant - Stock Titan
Director at Gossamer Bio (NASDAQ: GOSS) receives 115K stock options - Stock Titan
Gossamer Bio (GOSS) director awarded 115,000 stock options as compensation - Stock Titan
Gossamer Bio (NASDAQ: GOSS) awards director 115,000 stock options - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Gossamer Bio, Inc. Announces Early Settlement and New Indenture for Senior Secured Convertible Notes Due 2030 - Minichart
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - BioSpace
GOSS: Gossamer Bio Announces Early Tender Results for Exchange O - GuruFocus
Gossamer Bio receives 90.5% tender in debt exchange offer By Investing.com - Investing.com Nigeria
Gossamer Bio receives 90.5% tender in debt exchange offer - Investing.com
How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals - Yahoo Finance
Gossamer Bio Extends Early Tender Deadline for Convertible Note Exchange Offer to June 9 - geneonline.com
GOSS: Gossamer Bio Extends Tender Date for Convertible Notes Exc - GuruFocus
Gossamer Bio, Inc. Extends Early Tender Date for Exchange Offer and Consent Solicitation for Convertible Notes - Minichart
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Gossamer Bio extends early tender date for exchange offer; $181.05M tendered, New Notes up to $72M - TradingView
Gossamer Bio (NASDAQ: GOSS) extends early tender deadline in major convertible note exchange - Stock Titan
Pomerantz LLP Notifies Shareholders of Lawsuit Filed Against Gossamer Bio, Inc. – GOSS - ACCESS Newswire
GOSS, Gossamer Bio Faces Class Action Lawsuit Over PROSERA Trial Results - GuruFocus
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who - GuruFocus
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - Business Wire
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of - GlobeNewswire
Pomerantz LLP Posts Reminder: Legal Action Filed Against Gossamer Bio, Inc. – GOSS - ACCESS Newswire
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) In - GuruFocus
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - PR Newswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus
GOSS DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class ActionGOSS - ACCESS Newswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
GOSS DEADLINE TOMORROW: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class ActionGOSS - TMX Newsfile
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. ... - Black Hills Pioneer
GOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With - GlobeNewswire
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class ActionGOSS - TMX Newsfile
GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses Ma - GuruFocus
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):